title: Scheduling of monoaminergic neurotransmitter receptor expression in the primate neocortex during postnatal development.
abstract: Quantitative in vitro autoradiography was used to study the postnatal development of monoaminergic receptors (D1 and D2 dopaminergic, 5-HT1 and 5-HT2 serotonergic, and alpha 1, alpha 2, and beta noradrenergic sites) in the prefrontal, primary motor, somatosensory, and visual cortex of rhesus monkeys at birth and 1, 2, 4, 8, 12, 36, and 60 months of age. The density of all receptors studied increased rapidly within the first 2 postnatal months to levels as high as two times that recorded in the adults. After the fourth month, receptor density began a decline that subsided around the time of puberty. This course of developmental change was similar in all cortical layers and in all regions examined. However, the magnitude of the transient overproduction and eventual reduction in receptor density varied across the cortical layers and cytoarchitectonic areas in a manner specific to the individual receptor sites. Overall, cortical maturation was associated with the increased tendency of monoaminergic receptors to concentrate preferentially in the superficial cortical layers. The common developmental course of monoaminergic receptors in diverse cytoarchitectonic areas reveals an impressive coordination in the expression and regulation of these functionally relevant proteins in the cerebral cortex during infancy and adolescence.
authors.affiliation: Section of Neurobiology, Yale University School of Medicine, New Haven, Connecticut 06510.
authors.forename: M S
authors.initials: MS
authors.lastname: Lidow
authors.forename: P
authors.initials: P
authors.lastname: Rakic
mesh_terms: D000375:Aging / Q000378:metabolism*; D000818:Animals; D000831:Animals, Newborn; D001345:Autoradiography; D001552:Benzazepines / Q000378:metabolism; D002540:Cerebral Cortex / Q000254:growth & development / Q000378:metabolism*; D065127:Dopamine D2 Receptor Antagonists; D005260:Female; D008253:Macaca mulatta; D008297:Male; D009928:Organ Specificity; D020891:Raclopride; D011941:Receptors, Adrenergic / Q000378:metabolism; D017447:Receptors, Dopamine D1 / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D017981:Receptors, Neurotransmitter / Q000378:metabolism*; D011985:Receptors, Serotonin / Q000378:metabolism; D012457:Salicylamides / Q000378:metabolism; D014316:Tritium
chemical_list: D001552:Benzazepines; D065127:Dopamine D2 Receptor Antagonists; D011941:Receptors, Adrenergic; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D017981:Receptors, Neurotransmitter; D011985:Receptors, Serotonin; D012457:Salicylamides; D014316:Tritium; D020891:Raclopride